Category Archives: Byetta

FDA Backtracks Over GLP-1s’ Effects on Pancreas

The U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a link between GLP-1 drugs used to treat type 2 diabetes and pancreatic maladies, including acute pancreatitis and pancreatic cancer. GLP-1 drugs, which work by stimulating the body to produce insulin, include Bristol-Myers Squibb’s Byetta and … Continue reading FDA Backtracks Over GLP-1s’ Effects on Pancreas

Weekly Type 2 Drug to Be Delivered Via Needle Patch

A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system. The drug, now under development by Novo Nordisk, is semaglutide, a GLP-1 (glucagon-like peptide) receptor agonist that the company is hoping to introduce as a … Continue reading Weekly Type 2 Drug to Be Delivered Via Needle Patch

First-World Type 2 Drug Market to Reach $47 Billion by 2022

A Massachusetts-based research firm concludes that the first-world market for type 2 drugs and treatments will increase from $27 billion in sales in 2012 to $47 billion in 2022. The firm, Decision Resources, says increased sales in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom, will come from both an increase … Continue reading First-World Type 2 Drug Market to Reach $47 Billion by 2022

Type 2: Oramed Sends Oral Insulin Test Request to FDA

Israel-based Oramed announced that it has sent an application to the Food and Drug Administration for permission to enter Phase 2 trials of its oral insulin product. The company has been working on developing a means of delivering insulin orally, which would allow people with diabetes to avoid having to inject themselves with the hormone. … Continue reading Type 2: Oramed Sends Oral Insulin Test Request to FDA

Lilly Says Its New Injectible Outperforms Three Popular Diabetes Drugs

Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies. According to Lilly, dulaglutide, a GLP-1 analog, worked better to … Continue reading Lilly Says Its New Injectible Outperforms Three Popular Diabetes Drugs

Am I Doing the Right Thing?

Readers occasionally ask us for advice about drugs they are taking. When they do, we refer their questions to a medical professional. In the question below, a Florida reader expresses concerns about the interaction of her diabetes drug with the medicines she takes for asthma. Dear Diabetes Health: I am asthmatic and was diagnosed with … Continue reading Am I Doing the Right Thing?

FDA Gives Long-Awaited Nod to Amylin’s Bydureon

After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year. The drug is … Continue reading FDA Gives Long-Awaited Nod to Amylin’s Bydureon